Sentences with phrase «patients by reducing inflammation»

IMPROVING QUALITY OF LIFE IN CHRONICALLY ILL PATIENTS BY REDUCING INFLAMMATION AND OPTIMIZING MUSCLE MASS & FUNCTION Trumbull Marriott Merritt Parkway, Trumbull, CT

Improving Quality of Life in Chronically Ill Patients by Reducing Inflammation and Optimizing Muscle Mass and Function - AUDIO ONLY.

Not exact matches

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

«Piezosurgery may be a viable alternative to traditional osteotomy [bone - cutting] technique, as it reduces the degree of inflammation, pain, swelling, and morbidity, improving satisfaction and patient comfort,» according to the report by Dr. Gilberto Sammartino of University of Naples Federico II, Italy, and colleagues.

The ability to counteract inflammation in the lungs by utilising the combined anti-inflammatory and reparative properties of MSCs could potentially reduce the inflammatory response in individuals with chronic lung disease whilst also restoring lung function in these patients.

«With information about delirium risk, doctors can take steps before, during, and after surgery to reduce that risk,» for example, by reducing inflammation in patients with higher levels of CRP.

They then discovered that patients with celiac disease had unusually low levels of lnc13 in their intestines, suggesting that reduced levels of this RNA may contribute to the inflammation seen in celiac disease by turning off the normal regulatory pathway.

Enhanced amyloidogenic processing of APP by the ß - site APP cleaving enzyme (BACE) and the γ - secretase complex and reduced clearance lead to increased intracellular levels of soluble oligomeric Aß, resulting in cellular dysfunction comprising e.g., synaptic failure, mitochondrial dysfunction, enhanced oxidative stress, neurotransmitter and neurotrophin depletion, inflammation, and apoptosis which is reflected in patients as clinical symptoms such as cognitive deficits [2, 3].

In fact, feeling thankful translated to better mood, higher sleep quality, and reduced inflammation in heart - failure patients, according to a new study published by the American Psychological Association.

How this drug works is by attacking cells that cause inflammation in joint tissues (or in the rapidly growing and inflamed skin of the psoriasis patient) reducing its function, thereby reducing the inflammation along with any painful symptoms.

A reduction in inflammation and pain is thought to have a knock - on effect in reducing the levels of fatigue felt by patients, in addition to increasing joint mobility, generally by way of a reduction in stiffness that is often felt in the joints of sufferers first thing in the morning.

Because much of the peripheral damage of cancer treatment is caused largely by oxidative stress and inflammation, increasing the body's antioxidant defense systems will drastically reduce side effects and limit suffering by the patient.

In rodents, ketogenic diets reduce reactive oxygen species in the brain34 and reduce central inflammation and reactive oxygen species in a model of multiple sclerosis.35 Two clinical papers have found that ketogenic diet feeding of 12 weeks to 6 months reduced signs of liver inflammation in obese patients with nonalcoholic fatty liver disease (in addition to improving various other physiological and biochemical variables).36, 37 Unfortunately, basic research into non-alcoholic fatty liver disease has been hampered by species differences between mice and humans in their hepatic reaction to ketogenic diets.38